Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Democrat-Controlled House Will Turn Up The Volume On Drug Pricing

Executive Summary

With US House of Representatives now controlled by Democrats, lower chamber of Congress will likely increase hearings and investigations into industry pricing practices, but any legislation will probably need to dovetail with President Trump’s agenda to advance.

You may also be interested in...



Part D Coverage Gap Discount Relief Misses Ride On Opioids Bill

Biopharma will continue to seek ways to pass legislation reducing the 70% discount in Medicare Part D coverage gap but it looks like industry's next chance will be after the November elections.

DTC Ad Price Disclosure Provision Stripped From US Funding Bill

Even though measure was blocked in Congress, it may still advance through regulation.

Medicare Part D Plans Can Start Negotiating Indication-Based Pricing This Fall

Policy exempts indications covered by protected classes policy, including cancer treatments.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124132

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel